The European Commission (EC) has granted marketing authorisation for Lilly’s Kisunla (donanemab) in early symptomatic Alzheimer’s disease (AD). 

It is approved in adults with mild cognitive impairment as well as those with mild dementia stages of AD with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes or non-carriers. 

“Kisunla demonstrated meaningful results in people with early symptomatic Alzheimer’s disease by significantly slowing cognitive and functional decline in our Phase III TRAILBLAZER-ALZ 2 study,” said Patrik Jonsson, Executive Vice President and President of Lilly International. “The data shows that the earlier patients are identified, diagnosed, and treated with Kisunla, the greater the response to treatment.” 

The excessive buildup of amyloid plaques in the brain may lead to memory and thinking issues associated with Alzheimer’s disease.  

Kisunla can help the body remove the excessive buildup of amyloid plaques and slow the decline that may diminish people’s ability to: remember new information, important dates and appointments; plan and organize; make meals; use household appliances; manage finances; and be left alone. 

It is the only once-monthly amyloid plaque-targeting therapy with evidence supporting completing course of treatment once amyloid is reduced to minimal levels. This may reduce infusion burden and treatment costs. 

Data has also shown that Kisunla can significantly reduce the risk of progressing to the next clinical stage of disease over 18 months. 

In the United States, Japan, China and many other countries, donanemab is approved for patients regardless of ApoE4 status. In the European Union, Kisunla is approved for patients who are ApoE4 heterozygotes or non-carriers. 

In June, the UK’s National Institute for Health and Care Excellence (NICE) ruled that the drug did not demonstrate sufficient benefit to justify its high cost.

Diana Turner, Deputy Editor, DDW